Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hypoglycemia and Glucagon

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...

Type I Diabetes III: Clinical Manifestations

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...

Hypoglycemia

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...

Type II Diabetes II: Pathophysiology

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Bluemomycin, a new naphthoquinone derivative from Streptomyces sp. with antimicrobial and cytotoxic properties.

Biotechnology letters·2021

Same author

Duck plague outbreak in a Chara-Chemballi duck farm.

Iranian journal of veterinary research·2020

Same author

Gross, histopathological and immunohistochemical study on strobilocercus of Taenia taeniaeformis infection in the liver of laboratory rats (Rattus norvegicus) in India.

Veterinary parasitology, regional studies and reports·2019

Same author

Gross, histopathology and molecular diagnosis of oesophagostomosis in sheep.

Journal of parasitic diseases : official organ of the Indian Society for Parasitology·2018

Same author

Bis(μ-chloro) bridged 1D Cu<sup>I</sup> and Cu<sup>II</sup> coordination polymer complex and mononuclear Cu<sup>II</sup> complex: Synthesis, crystal structure and biological properties.

Journal of photochemistry and photobiology. B, Biology·2018

Same author

In vitro and in vivo anticancer activity of 2-acetyl-benzylamine isolated from Adhatoda vasica L. leaves.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2017

Search research articles

Related Experiment Video

Updated: Jun 8, 2026

Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate

Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate

Published on: June 25, 2019

Glucagonoma syndrome.

B C Ravi Kumar¹, C Balachandran, L Sabitha

¹Department of skin and STD, Kasturba Medical College and Hospital Manipal-576119, India.

Indian Journal of Dermatology, Venereology and Leprology

|October 6, 2010

Summary

This summary is machine-generated.

Glucagonoma syndrome, a rare condition involving pancreatic tumors, can present diversely. Early diagnosis is crucial for managing symptoms like necrolytic migratory erythema and diabetes mellitus.

More Related Videos

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

Related Experiment Videos

Last Updated: Jun 8, 2026

Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate

Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate

Published on: June 25, 2019

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

Area of Science:

Endocrinology
Oncology
Dermatology

Background:

Glucagonoma is a rare neuroendocrine tumor originating from pancreatic alpha cells.
It is characterized by a distinct clinical triad: necrolytic migratory erythema, weight loss, and diabetes mellitus.
The syndrome's rarity and varied presentation can delay diagnosis.

Purpose of the Study:

To report two cases of glucagonoma syndrome.
To illustrate the diverse clinical manifestations of this rare condition.
To emphasize the importance of timely diagnosis and management.

Main Methods:

Case report analysis.
Clinical presentation review.
Diagnostic criteria assessment.

Main Results:

Two patients presented with glucagonoma syndrome.
Clinical features varied between the two cases, highlighting the syndrome's heterogeneity.
Diagnostic delays were noted, underscoring challenges in recognition.

Conclusions:

Glucagonoma syndrome requires a high index of suspicion due to its varied presentation.
Early diagnostic efforts are essential for improved patient outcomes.
Multidisciplinary management is often necessary for effective treatment.